Latest Capital Raisings News

Actinogen Medical reported a $15.38 million loss for FY2026 while progressing its lead Alzheimer's drug Xanamem toward pivotal trial results expected this November. The company secured regulatory alignment and strengthened its cash position to fund operations through mid-2027.

Australian Dairy Nutritionals reported a 47% reduction in net loss for FY26, driven by a 66% revenue jump in its nutritional powders segment, which now makes up 70% of total revenue.

Industrial Minerals Ltd has finalised its takeover of Galleon Metals, adding a 205km² gold exploration portfolio in WA’s Eastern Goldfields. The company also announced key board appointments, including a new Managing Director with direct Laverton expertise.

Argo Global Listed Infrastructure (ASX: ALI) reported a robust FY2026 with total assets rising to $529 million and a record fully franked dividend of 10 cents per share. The portfolio outperformed benchmarks, driven by strong gains in electric utilities and midstream energy sectors amid AI-driven data centre demand.

Syntara Limited’s FY2026 results show a 7.9% revenue decline and a 13.6% increase in net loss amid significant clinical progress, including FDA backing for its lead drug amsulostat and a successful $8.8 million capital raise.

RocketBoots reported a 9.7% revenue rise to A$724,815 but deepened its net loss to A$6.6 million, driven by heavy investment ahead of a major contract rollout and international growth.

MA Credit Income Trust (ASX:MA1) posted a robust 8.56% net return for FY2026, surpassing its target, alongside a fully subscribed $190.5 million capital raise and strategic buy-back initiatives.

AI Private Opportunities Trust (ASX: AIX) has completed its first reporting period, raising $267 million and beginning deployment into high-profile private AI companies including ByteDance and Databricks.

Biotron Limited posted a $1.52 million net loss for FY2026, driven by integration and R&D costs following its Sedarex acquisition, while progressing regulatory and clinical development for its SedRxTM anaesthetic and antiviral pipeline.

Clarity Pharmaceuticals reported a 67% increase in net loss to $107.2 million for FY26, driven by higher R&D spending, while advancing multiple Phase III trials and expanding manufacturing capacity ahead of commercialisation.

Clinuvel Pharmaceuticals marked its tenth consecutive profit with stable revenues and rising cash reserves, while accelerating U.S. expansion including a Nasdaq uplisting and potential ASX delisting.

Aeris Resources delivered a standout FY26 with revenues up 22% and profit after tax surging 295%, buoyed by operational gains and a strategic acquisition of Peel Mining.